Technical Analysis for CRBU - Caribou Biosciences, Inc.

Grade Last Price % Change Price Change
F 11.4 4.88% 0.53
CRBU closed down 6.37 percent on Tuesday, January 18, 2022, on 1.28 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Down
Historical CRBU trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 4.88%
180 Bearish Setup Bearish Swing Setup 4.88%
Lower Bollinger Band Walk Weakness 4.88%
New 52 Week Low Weakness 4.88%
Outside Day Range Expansion 4.88%
Wide Bands Range Expansion 4.88%
Below Lower BB Weakness 4.88%
Down 3 Days in a Row Weakness 4.88%
Down 4 Days in a Row Weakness 4.88%
Lower Bollinger Band Touch Weakness 4.88%
Older End-of-Day Signals for CRBU ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout 2 minutes ago
Up 5% 2 minutes ago
Up 3% about 3 hours ago
Up 2% about 3 hours ago
Rose Above Lower Bollinger Band about 3 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Caribou Biosciences, Inc. Description

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Solid Tumors Cancer Immunotherapy Cell Biology Cell Therapy Leukemia Multiple Myeloma Hematologic Malignancies Breakthrough Therapy Chimeric Antigen Receptor T Cell CD19 Refractory Acute Myeloid Leukemia T Cells Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia

Is CRBU a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 32.65
52 Week Low 10.8
Average Volume 401,607
200-Day Moving Average 0.00
50-Day Moving Average 16.94
20-Day Moving Average 13.99
10-Day Moving Average 12.63
Average True Range 1.14
ADX 27.82
+DI 11.13
-DI 30.76
Chandelier Exit (Long, 3 ATRs) 13.88
Chandelier Exit (Short, 3 ATRs) 14.22
Upper Bollinger Bands 17.11
Lower Bollinger Band 10.87
Percent B (%b) 0.0
BandWidth 44.63
MACD Line -1.55
MACD Signal Line -1.38
MACD Histogram -0.1722
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.37
Resistance 3 (R3) 12.51 12.16 12.12
Resistance 2 (R2) 12.16 11.77 12.09 12.04
Resistance 1 (R1) 11.51 11.54 11.34 11.37 11.95
Pivot Point 11.16 11.16 11.07 11.09 11.16
Support 1 (S1) 10.51 10.77 10.34 10.37 9.79
Support 2 (S2) 10.16 10.54 10.09 9.70
Support 3 (S3) 9.51 10.16 9.62
Support 4 (S4) 9.37